F.Y.I.
Monday April 13, 9:01 am Eastern Time
Company Press Release
Synthetic Blood International Announces Toxicology Director
KETTERING, Ohio--(BUSINESS WIRE)--April 13, 1998--Synthetic Blood International Inc. (OTCBB:SYBD - news) announced
today that Douglas J. Kornbrust, Ph.D., vice president and Scientific Director at Sierra Biomedical, a leading contract primate
testing facility for the pharmaceutical and biotechnology industries, has been named consultant Director of Preclinical Toxicology
and Pharmacology for the company.
Dr. Kornbrust, who holds a Ph.D. in toxicology, has previously held senior technical and management positions in toxicologic and
pharmacokinetic product development at ISIS Pharmaceuticals, Alliance Pharmaceuticals, Phone-Poulenc Rorer, and Merck. At
Alliance Pharmaceuticals, Kornbrust developed and implemented preclinical toxicology programs for their perfluorocarbon (PFC)
liquid ventilation and blood substitute products.
''His broad experience with preclinical product development and specifically with PFC product development is expected to
significantly enhance SYBD's capability to rapidly move our lead products to the clinical trial stage,'' said Robert Nicora, president.
SYBD is developing an artificial blood substitute emulsion (Oxycyte) and a liquid ventilation product (Fluorovent) based on
fluorocarbon technology pioneered by Leland C. Clark Jr., Ph.D., Director of Research. The Company is also developing an
implantable biosensor for continuously monitoring glucose levels in diabetics based on technology also developed by Dr. Clark.
Dr. Clark is a former Research Professor of Biological Sciences at Antioch University and a Distinguished Service Professor at the
University of Cincinnati School of Medicine.
SYBD is located in Kettering. The Company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD.
Contact:
Synthetic Blood International, Inc.
Joan Mahan, 800/809-6054 |
